CME webinars update dermatologists on diagnosing, treating pustular psoriasis
Challenging to diagnose, pustular psoriasis is a clinically heterogenous group of rare psoriasis subtypes characterized by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis (GPP), palmoplantar pustular psoriasis (PPPP), and acrodermatitis continua of Hallopeau (ACH). The differential diagnosis is wide and relies mainly on clinical features. In the case of GPP, which can be life-threatening, correct diagnosis is crucial. To help dermatologists accurately diagnose and effectively treat patients with pustular psoriasis, Rockpointe and the Potomac Center for Medical Education will offer a series of live CME/ABIM MOC-eligible/ABD MOC-eligible virtual presentations at meetings hosted by state chapters of the American Academy of Dermatology (AAD).
In recent years the European Rare and Severe Psoriasis Expert Network (ERASPEN) and the Japanese Dermatological Association have issued guidelines on diagnosis, classification, and assessment of severity. Current systemic treatment has involved cyclosporine, methotrexate, or acitretin, and the Japanese Dermatological Association has also published guidelines that include a treatment algorithm. However, recognition that IL-36 cytokines are likely the key driver of the autoimmune response in pustular psoriasis has led to development of two novel, investigational monoclonal antibodies that target the IL-36 receptor. Agents that target other molecules have also been investigated.
Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease is an hour-long program geared toward dermatologists, the clinicians responsible for management of patients with pustular psoriasis. Presenters will review the most recent guidelines for diagnosing, classifying, and assessing the severity of pustular psoriasis and will provide information on current treatment guidelines and agents in development to manage this rare group of disorders.
Dates and times
Tuesday, May 11, 2021
6:00 – 7:00 PM ET (5:00 – 6:00 PM CT / 3:00 – 4:00 PM PT)
Hosted by: Rhode Island Dermatology Society
Thursday, August 12, 2021
8:00 – 9:00 PM ET (7:00 – 8:00 PM CT / 5:00 – 6:00 PM PT)
Hosted by: Wisconsin Dermatological Society
Additional date and time*
Tuesday, May 4, 2021
7:15 – 8:15 PM ET (6:15 – 7:15 PM CT / 4:15 – 5:15 PM PT)
Hosted by: Pennsylvania Academy of Dermatology
*This talk is part of a combined meeting with the Pennsylvania Academy of Dermatology. To register for this talk, click here.
This free educational initiative is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine. At the program’s conclusion, participants should be able to:
- Discuss how the pathophysiology of pustular psoriasis differs from that of plaque psoriasis.
- Employ the most recent consensus recommendations to diagnose and classify pustular psoriasis.
- Apply the most recent guidelines when managing patients with pustular psoriasis.
- Assess the mechanism of action, efficacy, and safety of agents in development for managing pustular psoriasis.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education (PCME) and Rockpointe. PCME, which is accredited by the ACCME to provide continuing medical education for physicians, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Successful completion of this CME activity, which includes participation in the evaluation component, enables participants to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
Dermatologists certified by the American Board of Dermatology (ABD) must earn a minimum of 25 hours of AMA PRA Category 1 Credits™ annually. Half of these credits must be dermatology practice-specific CME credits from accredited organizations in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board-certified dermatologists in contributing toward this MOC requirement set forth by the ABD.
There is no fee for this activity, which is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. To receive credit, participants must register, view the live CME activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, such as managing challenges posed by COVID-19, addressing racial disparities in care, and combating the nation’s opioid crisis. As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy and Medicine. In addition, its popular Medical Education Exchange (MEDX) CME regional meetings include sessions on the basics of quality improvement and alternative payment models, as well as relevant and scientifically accurate sessions on numerous disease states. All sessions include links back to associated National Quality Priorities to reinforce the bigger picture and the triple aim of: 1) improving health and 2) lowering cost to 3) better the patient experience. At Rockpointe, education equals quality.
For more details and to register for Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease, go to https://www.pathlms.com/rockpointe/courses/28256 or click here.
